Ibrunat Capsule contains Ibrutinib 140 mg, a potent Bruton’s tyrosine kinase (BTK) inhibitor indicated for the treatment of various B-cell malignancies, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia (WM). Ibrutinib selectively binds to BTK, a critical enzyme involved in B-cell receptor signaling, thereby inhibiting malignant B-cell proliferation and survival. This targeted mechanism of action results in decreased tumor growth and improved patient outcomes. Ibrunat is administered orally, allowing convenient dosing and improved patient compliance. Clinical studies have demonstrated its efficacy in both treatment-naïve and relapsed/refractory patients, with significant improvements in progression-free survival and overall response rates. Common adverse effects include diarrhea, fatigue, neutropenia, thrombocytopenia, and infections, necessitating regular monitoring of blood counts and clinical status during therapy. Dose adjustments may be required in cases of severe toxicity. Ibrunat should be used under strict medical supervision, particularly in patients with bleeding risks or concomitant anticoagulant therapy, due to potential hemorrhagic complications. It is contraindicated in patients with known hypersensitivity to Ibrutinib or its excipients. Overall, Ibrunat Capsule represents a valuable therapeutic option in the management of B-cell malignancies, offering targeted efficacy with an acceptable safety profile.